Drugs / Tonabacase
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05329168 | May 2022 → Aug 2023 | infective endocarditis, staphylococcus aureus infection | Lysovant | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tonabacase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05329168 ↗ |
| Known as | LSVT-1701 | “Tonabacase (LSVT-1701)” NCT05329168 ↗ |
| Modality | Protein / enzyme biologic | “endolysin-derived LSVT-1701 (tonabacase)” NCT05329168 ↗ |
| Route | Intravenous | “4.5 or 6.0 mg/kg IV once daily for 4 days” NCT05329168 ↗ |